Updates are available Correction dated 2022-12-08
Click to view Correction: https://doi.org/10.1186/s12889-022-14741-1
-
Authors
Hussein, Humaira
Nevill, Clareece R.
Meffen, Anna
Abrams, Keith R.
Bujkiewicz, Sylwia
Sutton, Alex J.
Gray, Laura J.
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/R025223/1, MR/R025223/1, MR/R025223/1, MR/R025223/1, MR/R025223/1)
National Institute for Health and Care Research
George Davies Charitable Trust
- License Information
-
More Information
Article History
Received: 18 July 2022
Accepted: 15 September 2022
First Online: 27 September 2022
Change Date: 8 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12889-022-14741-1
Declarations
:
: Not applicable.
: Not applicable.
: KRA is a member of the National Institute for Health and Care Excellence (NICE) Diagnostics Advisory Committee, the NICE Decision and Technical Support Units, and is a National Institute for Health Research (NIHR) Senior Investigator <i>Emeritus</i> [NF-SI-0512-10159]. He has served as a paid consultant, providing unrelated methodological and strategic advice, to the pharmaceutical and life sciences industry generally, as well as to DHSC/NICE, and has received unrelated research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics/Clearblue. He has also received course fees from ABPI and is a Partner and Director of Visible Analytics Limited, a health technology assessment consultancy company. All other authors (HH, CN, AM, SB, AS, LG) have no conflicts of interest.
